The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer

Annals of Surgical Oncology

Volumn 11, Issue 10, 2004, Pages 928-933

  Tamura, Masaya ^a   Oda, Makoto ^a   Matsumoto, Isao ^a   Tsunezuka, Yoshio ^a   Kawakami, Kazuyuki ^a   Ohta, Yasuhiko ^b   Watanabe, Go ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Enzyme linked immunosorbent assay; Lymph node metastasis; Matrix metalloproteinase 9; Vascular endothelial growth factor; Vascular endothelial growth factor C

Indexed keywords

GELATINASE B; VASCULOTROPIN; VASCULOTROPIN C; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROBABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; BIOASSAY; BLOOD; CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOLOGICAL ASSAY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 14644412993     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.01.013     Document Type: Article

References (16)

1. Laack E, Köhler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-7.
2. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001;85:255-60.
3. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe G. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and deceased nm 23 expression associated with microdissemination in the lymph nodes in stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2000;119:804-13.
4. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary non-small cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003;98:1217-22.
5. Tamura M, Ohta Y, Tsunezuka Y, et al. Chest computed tomography and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cel lung cancer. Chest 2004;126:342-6.
6. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995;6:1059-62.
7. Ohta Y, Watanabe Y, Murakami S, et al. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 1997;76(8):1041-5.
8. Tamura M, Ohta Y, Kajita T, et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001;8:1097-102.
9. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp Med 2001;95:1-4.
10. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenic factors and matrix metalloproteinases upon tumor progression in non-small cell lung cancer. Br J Cancer 2001;85:1706-12.
11. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149-53.
12. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52:4589-49.
13. Ylisirnio S, Höyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311-6.
14. Guan K, Ye H, Yan Z, Wang Y, Hou S. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003;61:719-24.
15. Faris E, Ranuncolo S, Cresta C, et al. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89:389-94.
16. John M, Oltmanns U, Witt C, and Jung K. Re: elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp Med 2002;96:126-7.